Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.Completed
NCT05878522Phase 1Updated Dec 6, 2024
Sponsor: Pfizer
Healthy
United States
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100Completed
NCT01534052Phase 2Updated Dec 6, 2024
Sponsor: Astellas Pharma Inc
Castration-Resistant Prostate Cancer (CRPC)
United States, Moldova, South Africa
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompleted
NCT02799745Phase 2Updated Dec 6, 2024
Sponsor: Astellas Pharma Global Development, Inc.
Prostate Cancer
United States, Canada
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerCompleted
NCT02116582Phase 4Updated Dec 6, 2024
Sponsor: Astellas Pharma Europe B.V.
Metastatic Castration-Resistant Prostate Cancer
Belgium, France, Germany, Spain, United Kingdom
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular CarcinomaCompleted
NCT02528643Phase 2Updated Dec 6, 2024
Sponsor: Astellas Pharma Global Development, Inc.
Advanced Hepatocellular Carcinoma
United States, Canada, Hong Kong, Italy, Puerto Rico +4 more
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideCompleted
NCT01977651Phase 4Updated Dec 6, 2024
Sponsor: Astellas Pharma Global Development, Inc.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
United States, Argentina, Australia, Belgium, Canada +15 more
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and OlderCompleted
NCT04754594Phase 2, Phase 3Updated Dec 6, 2024
Sponsor: BioNTech SE
SARS-CoV-2 Infection · COVID-19 · Maternal Immunization
United States, Brazil, South Africa, Spain, United Kingdom
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerCompleted
NCT01288911Phase 2Updated Dec 6, 2024
Sponsor: Astellas Pharma Inc
Prostatic Neoplasms
United States, Belgium, Canada, Denmark, France +3 more
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruiting
NCT04985266Phase 2Updated Dec 5, 2024
Sponsor: Royal Marsden NHS Foundation Trust
ER+ Breast Cancer · HER2-negative Breast Cancer
France, United Kingdom
ImPROving Quality of LIFe in the Long COVID PatientCompleted
NCT05823896Phase 2Updated Dec 4, 2024
Sponsor: Karolinska Institutet
Post-COVID-19 Syndrome · Long COVID · Long Covid19 · COVID-19
Sweden
PL_GNT01_ISR_Grant 53234273Unknown
NCT06714019N/AUpdated Dec 3, 2024
Sponsor: National Institute of Cardiology, Warsaw, Poland
Transthyretin Cardiomyopathy (TTR-CM) · Transthyretin (TTR) Amyloid Cardiomyopathy · Transthyretin Amyloidosis
Poland
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical TrialsCompleted
NCT00828919NAUpdated Dec 3, 2024
Sponsor: Pfizer
Solid Tumors
United States, Czechia, France, Germany, Hungary +6 more
Treatment Resistance Following Anti-cancer TherapiesTerminated
NCT04436120NAUpdated Dec 3, 2024
Sponsor: Pfizer
Disease Progression
United States, Argentina, Belgium, France, United Kingdom
Affect of Duavive on Mood & Anxiety SymptomsRecruiting
NCT04478305Phase 1Updated Dec 3, 2024
Sponsor: St. Joseph's Healthcare Hamilton
Menopause · Depression, Anxiety · Sleep · Menopause Related Conditions
Canada
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.Completed
NCT05668091Phase 2Updated Dec 2, 2024
Sponsor: Harlan M Krumholz
Long COVID
United States
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTorNot Yet Recruiting
NCT06218069Phase 2, Phase 3Updated Nov 29, 2024
Sponsor: Radboud University Medical Center
NSCLC
Germany, Netherlands
Drug Use Investigation of COMIRNATY Intramuscular InjectionCompleted
NCT04815031N/AUpdated Nov 27, 2024
Sponsor: Pfizer
COVID-19
Japan
ToFAcitinib in Early Active Axial SpondyloarThritis:Recruiting
NCT06112665Phase 4Updated Nov 26, 2024
Sponsor: Charite University, Berlin, Germany
Axial Spondyloarthritis
Germany
Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine MonotherapyCompleted
NCT04736576NAUpdated Nov 22, 2024
Sponsor: Pfizer
Breast Cancer
Japan
Transthyretin Amyloidosis Outcome Survey (THAOS)Completed
NCT00628745N/AUpdated Nov 22, 2024
Sponsor: Pfizer
Transthyretin Gene Mutations · Transthyretin Amyloidosis
United States, Argentina, Belgium, Brazil, Bulgaria +20 more
Voxelotor CYP and Transporter Cocktail Interaction StudyCompleted
NCT05981365Phase 1Updated Nov 22, 2024
Sponsor: Pfizer
Sickle Cell Disease
United States
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedCompleted
NCT02530320Phase 2Updated Nov 22, 2024
Sponsor: Grupo Español de Investigación en Neurooncología
Oligodendroglioma · Oligoastrocytoma
Spain
Treatment Patterns Among Patients With Venous Thromboembolism in the United StatesCompleted
NCT05795062N/AUpdated Nov 22, 2024
Sponsor: Pfizer
Venous Thromboembolism
United States
A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older AdultsCompleted
NCT05788237Phase 1Updated Nov 22, 2024
Sponsor: Pfizer
Healthy
Argentina
Long-Term Specified Drug Use-Results Survey for Xtandi CapsuleCompleted
NCT02669771N/AUpdated Nov 21, 2024
Sponsor: Astellas Pharma Inc
Castration-resistant Prostate Cancer
Japan

Previous page Next page